Cart
sales@molnova.com
JAK3/BTK-IN-1
CAS No. 2674036-91-8
JAK3/BTK-IN-1( —— )
Catalog No. M37669 CAS No. 2674036-91-8
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 586 | In Stock |
|
| 10MG | 834 | In Stock |
|
| 25MG | 1264 | In Stock |
|
| 50MG | 1600 | In Stock |
|
| 100MG | 2409 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK3/BTK-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases.
-
DescriptionJAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK | JAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2674036-91-8
-
Formula Weight456.54
-
Molecular FormulaC25H28N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C1=C2C(=CNC2=NC(NC3=CN(CC)N=C3)=N1)C4=CC=CC=C4)[C@H]5CN(C(C=C)=O)CCC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guobao Zhang, et al. Pyrimidopyrroles. Patent WO2021147952A1.
molnova catalog
related products
-
PCI-29732
A selective and irreversible Btk inhibitor with biochemical Ki of 8.2 nM.
-
TL-895
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.
-
BDTX-189
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
